How will the Senate grill pharma?
Public pressure over drug prices has forced the hand of a number of the nation's biggest pharma companies, which have agreed to dispatch their executives to testify before the Senate later this month.
They’ll undoubtedly arrive with talking points and a determination to stay laser-focused on message. But they're also expected to face a tough room. STAT’s Ed Silverman has seven questions that execs like Merck’s Kenneth Frazier and Johnson & Johnson’s Jennifer Taubert might face — including zingers like, “Why do your companies oppose more transparency of R&D costs?”
They’ll undoubtedly arrive with talking points and a determination to stay laser-focused on message. But they're also expected to face a tough room. STAT’s Ed Silverman has seven questions that execs like Merck’s Kenneth Frazier and Johnson & Johnson’s Jennifer Taubert might face — including zingers like, “Why do your companies oppose more transparency of R&D costs?”
.png)
No hay comentarios:
Publicar un comentario